These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 2983161)

  • 1. Interaction of PHM, PHI and 24-glutamine PHI with human VIP receptors from colonic epithelium: comparison with rat intestinal receptors.
    Laburthe M; Couvineau A; Rouyer-Fessard C; Moroder L
    Life Sci; 1985 Mar; 36(10):991-5. PubMed ID: 2983161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.
    Zawilska JB; Dejda A; Niewiadomski P; Gozes I; Nowak JZ
    J Mol Neurosci; 2005; 25(3):215-24. PubMed ID: 15800375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart receptors for VIP, PHI and secretin are able to activate adenylate cyclase and to mediate inotropic and chronotropic effects. Species variations and physiopathology.
    Christophe J; Waelbroeck M; Chatelain P; Robberecht P
    Peptides; 1984; 5(2):341-53. PubMed ID: 6089134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of GRF with VIP receptors and stimulation of adenylate cyclase in rat and human intestinal epithelial membranes. Comparison with PHI and secretin.
    Laburthe M; Amiranoff B; Boige N; Rouyer-Fessard C; Tatemoto K; Moroder L
    FEBS Lett; 1983 Aug; 159(1-2):89-92. PubMed ID: 6307754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [D-Phe4]peptide histidine-isoleucinamide ([D-Phe4]PHI), a highly selective vasoactive-intestinal-peptide (VIP) agonist, discriminates VIP-preferring from secretin-preferring receptors in rat pancreatic membranes.
    Robberecht P; Coy DH; De Neef P; Camus JC; Cauvin A; Waelbroeck M; Christophe J
    Eur J Biochem; 1987 Jun; 165(2):243-9. PubMed ID: 3036504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The receptors of the VIP family peptides (VIP, secretin, GRF, PHI, PHM, GIP, glucagon and oxyntomodulin). Specificities and identity.
    Rosselin G
    Peptides; 1986; 7 Suppl 1():89-100. PubMed ID: 3018707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of PHI on vasoactive intestinal peptide receptors and adenylate cyclase activity in lung membranes. A comparison in man, rat, mouse and guinea pig.
    Robberecht P; Tatemoto K; Chatelain P; Waelbroeck M; Delhaye M; Taton G; De Neef P; Camus JC; Heuse D; Christophe J
    Regul Pept; 1982 Oct; 4(5):241-50. PubMed ID: 6294750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasoactive intestinal peptide effects on GH3 pituitary tumor cells: high affinity binding, affinity labeling, and adenylate cyclase stimulation. Comparison with peptide histidine isoleucine and growth hormone-releasing factor.
    Wood CL; O'Dorisio MS; Vassalo LM; Malarkey WB; O'Dorisio TM
    Regul Pept; 1985 Nov; 12(3):237-48. PubMed ID: 3001842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of a high-affinity VIP receptor in human lung parenchyma.
    Schachter M; Dickinson KE; Miles CM; Sever PS
    FEBS Lett; 1986 Apr; 199(1):125-9. PubMed ID: 3007215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a potential receptor for both peptide histidine isoleucine and peptide histidine valine.
    Tse DL; Pang RT; Wong AO; Chan SM; Vaudry H; Chow BK
    Endocrinology; 2002 Apr; 143(4):1327-36. PubMed ID: 11897689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line, HT-29.
    Couvineau A; Rousset M; Laburthe M
    Biochem J; 1985 Oct; 231(1):139-43. PubMed ID: 2998337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High affinity peptide histidine isoleucine-preferring receptors in rat liver.
    Paul S; Chou J; Kubota E
    Life Sci; 1987 Nov; 41(21):2373-80. PubMed ID: 2824950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The human vasoactive intestinal peptide receptor: molecular identification by covalent cross-linking in colonic epithelium.
    Couvineau A; Laburthe M
    J Clin Endocrinol Metab; 1985 Jul; 61(1):50-5. PubMed ID: 2987295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of peptides related to VIP and secretin with guinea pig pancreatic acini.
    Zhou ZC; Gardner JD; Jensen RT
    Am J Physiol; 1989 Feb; 256(2 Pt 1):G283-90. PubMed ID: 2465694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebral vascular adenylate cyclase: evidence for coupling to receptors for vasoactive intestinal peptide and parathyroid hormone.
    Huang M; Rorstad OP
    J Neurochem; 1984 Sep; 43(3):849-56. PubMed ID: 6086840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of thymic peptide thymosin alpha 1 with VIP receptors in rat intestinal epithelial cells: comparison with PHI and secretin.
    Calvo JR; Guerrero JM; Goberna R
    Gen Pharmacol; 1989; 20(4):503-5. PubMed ID: 2546855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice.
    Rangon CM; Goursaud S; Medja F; Lelièvre V; Mounien L; Husson I; Brabet P; Jégou S; Janet T; Gressens P
    J Pharmacol Exp Ther; 2005 Aug; 314(2):745-52. PubMed ID: 15872042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of vasoactive intestinal peptide receptors in human colonic epithelial cells.
    Broyart JP; Dupont C; Laburthe M; Rosselin G
    J Clin Endocrinol Metab; 1981 Apr; 52(4):715-21. PubMed ID: 6259191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a common VIP-PACAP receptor in human small intestinal epithelium.
    Salomon R; Couvineau A; Rouyer-Fessard C; Voisin T; Lavallée D; Blais A; Darmoul D; Laburthe M
    Am J Physiol; 1993 Feb; 264(2 Pt 1):E294-300. PubMed ID: 8383439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
    Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
    J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.